Abstract

Background:The Movement Disorder Society diagnostic criteria for progressive supranuclear palsy introduced the diagnostic certainty level “suggestive of progressive supranuclear palsy” for clinical conditions with subtle signs, suggestive of the disease. This category aims at the early identification of patients, in whom the diagnosis may be confirmed as the disease evolves.Objective:To assess the diagnostic performance of the defined clinical conditions suggestive of progressive supranuclear palsy in an autopsy-confirmed cohort.Methods:Diagnostic performance of the criteria was analyzed based on retrospective clinical data of 204 autopsy-confirmed patients with progressive supranuclear palsy and 216 patients with other neurological diseases.Results:The conditions suggestive of progressive supranuclear palsy strongly increased the sensitivity compared to the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy criteria. Within the first year after symptom onset, 40% of patients with definite progressive supranuclear palsy fulfilled criteria for suggestive of progressive supranuclear palsy. Two-thirds of patients suggestive of progressive supranuclear palsy evolved into probable progressive supranuclear palsy after an average of 3.6 years. Application of the criteria for suggestive of progressive supranuclear palsy reduced the average time to diagnosis from 3.8 to 2.2 years.Conclusions:Clinical conditions suggestive of progressive supranuclear palsy allow earlier identification of patients likely to evolve into clinically possible or probable progressive supranuclear and to have underlying progressive supranuclear palsy pathology. Further work needs to establish the specificity and positive predictive value of this category in real-life clinical settings, and to develop specific biomarkers that enhance their diagnostic accuracy in early disease stages.

Highlights

  • Max-Joseph Grimm and Gesine Respondek contributed to this article

  • Patients with autopsy-confirmed diagnoses of Progressive supranuclear palsy (PSP),10–12 corticobasal degeneration (CBD),13 multiple system atrophy (MSA) with a clinical diagnosis of MSA with predominant parkinsonism (MSA-P),14 Lewy body disease (LBD)15 with clinical history of Parkinson’s disease (PD), and 4R-tau negative frontotemporal lobar degeneration16 were identified in the registries of nine collaborating brain banks with expertise in neurodegenerative disorders: DIAGNOSTIC PERFORMANCE

  • A total of 204 patients with autopsy confirmed PSP, and 216 cases with other neurological disease with detailed clinical records were included in our analysis

Read more

Summary

Objective

We analyzed a large, clinically welldescribed cohort of autopsy-confirmed PSP patients and disease controls for (1) the sensitivity, specificity and positive predictive value (PPV) of s.o. PSP to predict underlying PSP pathology as a function of disease duration, (2) the effect of the exclusion criteria thereon, (3) evolution of patients with s.o. PSP into possible and probable PSP, (4) the impact of s.o. PSP on the overall diagnostic performance of the MDS-PSP criteria as compared to the NINDS-SPSP criteria, and (5) the distribution of PSP-predominance types among s.o. PSP with and without PSP pathology

Methods
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call